Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Diseases, Genetic Clear all
Recruiting No phase listed Observational

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

NCT06732414
View directory record Official record
Conditions
Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 4:05 PM EDT
Not listed No phase listed Observational

Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00005900
View directory record Official record
Conditions
I Cell Disease, Fucosidosis, Globoid Cell Leukodystrophy, Adrenoleukodystrophy, Mannosidosis, Niemann-Pick Disease, Pulmonary Complications, Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Metachromatic Leukodystrophy, Gaucher's Disease, Wolman Disease
Interventions
Not listed
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT00462709
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
48
States / cities
Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 4:05 PM EDT
Recruiting Phase 4 Interventional

Ethnic Differences in Mechanisms of Action of Dupilumab

NCT05268107
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Retrospective Study to Evaluate the Effectiveness of the Ulthera System

NCT01519934
View directory record Official record
Conditions
Skin Laxity, Wrinkles
Interventions
Not listed
Lead sponsor
Ulthera, Inc
Industry
Eligibility
25 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

NCT06923228
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 17, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 17, 2026, 4:05 PM EDT
Completed No phase listed Observational

An Exploratory Genetic Study in Participants With Psoriasis

NCT02155192
View directory record Official record
Conditions
Psoriasis
Interventions
No Intervention
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Bakersfield, California • Los Angeles, California • Ocala, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 17, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)

NCT07567131
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Porphyria (XLP)
Interventions
Not listed
Lead sponsor
Portal Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Wake Forest, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

NCT04823130
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab (SAR231893)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 17, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

NCT00478244
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
busulfan, cyclophosphamide, fludarabine phosphate, hematopoietic bone marrow transplantation
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 17, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
View directory record Official record
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

NCT03725722
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation

NCT06105541
View directory record Official record
Conditions
Hypermobile Ehlers-Danlos Syndrome, Hypermobile Spectrum Disorder, Ehlers-Danlos Syndrome
Interventions
Transcutaneous Auricular Neurostimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 17, 2026, 4:05 PM EDT
Completed No phase listed Observational

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

NCT07009262
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Inapplicable
Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 4:05 PM EDT
Available No phase listed Expanded access

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

NCT05795361
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT
Drug
Lead sponsor
Takeda
Industry
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Phoenix, Arizona • Oakland, California • Wilmington, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

NCT01415427
View directory record Official record
Conditions
Mucopolysaccharidosis IV A, Morquio A Syndrome, MPS IVA
Interventions
BMN 110 - Weekly, BMN 110 - Every Other Week
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Oakland, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

NCT02595073
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 17, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Osteogenesis Imperfecta Blood Pressure Study

NCT04169568
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Manual cuff blood pressure
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
1 Year to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 17, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pure Impact Treatment to Strengthen and Tone Abdomen, Quadriceps and Glutes Muscles

NCT07094971
View directory record Official record
Conditions
Muscle Tone, Muscle Strength
Interventions
Pure Impact
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
25 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 17, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Vitamin D Deficiency and Atopic Dermatitis

NCT01337635
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency
Interventions
Vitamin D
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 17, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Standing Cognition and Co-morbidities of POTS Evaluation

NCT03602482
View directory record Official record
Conditions
Postural Tachycardia Syndrome, Ehlers-Danlos Syndrome
Interventions
Standing, Supine
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
13 Years to 60 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 17, 2026, 4:05 PM EDT